The top analyst upgrades, downgrades and other research calls from Monday include CalAmp, Fiat Chrysler, Lowe's, Plains All American and Ulta Beauty.
Tetraphase Pharmaceuticals continues to reel from the spectacular and unexpected failure of its flagship candidate, eravacycline.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and added some color.
Source: ThinkstockEarnings season has wound down for the most part, and Tuesday’s market reaction saw a drop of just over 1 point on the S&P 500 (closed at 2,002.28) and the Dow closed down almost...
SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving clinical and FDA catalysts during the remainder of 2015.
Wednesday’s top analyst upgrades, downgrades and initiations include Celgene, Ciena, Goldman Sachs, MannKind, Newfield Exploration, Tetraphase Pharmaceuticals, Walgreens Boots Alliance and Yingli...
Source: ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some health care professionals. Their overuse in some cases has led many...
The top analyst upgrades, downgrades and initiations seen on Monday included Chipotle Mexican Grill, Delphi Technologies, Dollar General, Facebook, Ingersoll-Rand, Nike, Okta and Quest Diagnostics.
A new SunTrust Robinson Humphrey research report focuses in on biotech companies that have upcoming clinical data that could prove to be huge.
The top analyst upgrades, downgrades and other research calls from Tuesday include Agilent, Apple, Citigroup, Exxon, M&T Bank, Snap, Toyota and Twitter.
The top analyst upgrades, downgrades and other research calls from Wednesday include Avis Budget, Blue Apron, Chipotle Mexican Grill, Domino's, Northrop Grumman, Pepsico, Rio Tinto, T-Mobile and...
The top analyst upgrades, downgrades and other research calls from Monday include American Express, Cisco, First Solar, Goldman Sachs, Nasdaq, Shopify, SunPower and Workday.
When investors see a drop of almost 80% in a share price, the question of long-term viability is almost impossible to ignore.
Whether the market wants to sell off or wants to again go back and challenge all-time highs, a slew of companies have filed to raise billions of dollars worth of capital.
From BioHealth Investor by Mark S. Senak As the lame duck Senate gets ready to waddle off to their place in history, they have moved to pass S. 3546 – a bill that would require the makers of...